CA2736381A1 - Methods of using sustained release aminopyridine compositions - Google Patents

Methods of using sustained release aminopyridine compositions Download PDF

Info

Publication number
CA2736381A1
CA2736381A1 CA2736381A CA2736381A CA2736381A1 CA 2736381 A1 CA2736381 A1 CA 2736381A1 CA 2736381 A CA2736381 A CA 2736381A CA 2736381 A CA2736381 A CA 2736381A CA 2736381 A1 CA2736381 A1 CA 2736381A1
Authority
CA
Canada
Prior art keywords
aminopyridine
subject
multiple sclerosis
sustained release
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2736381A
Other languages
English (en)
French (fr)
Inventor
Andrew R. Blight
Ron Cohen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acorda Therapeutics Inc
Original Assignee
Acorda Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41799491&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2736381(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Acorda Therapeutics Inc filed Critical Acorda Therapeutics Inc
Publication of CA2736381A1 publication Critical patent/CA2736381A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA2736381A 2008-09-10 2009-09-10 Methods of using sustained release aminopyridine compositions Abandoned CA2736381A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9579708P 2008-09-10 2008-09-10
US61/095,797 2008-09-10
PCT/US2009/056476 WO2010030755A1 (en) 2008-09-10 2009-09-10 Methods of using sustained release aminopyridine compositions

Publications (1)

Publication Number Publication Date
CA2736381A1 true CA2736381A1 (en) 2010-03-18

Family

ID=41799491

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2736381A Abandoned CA2736381A1 (en) 2008-09-10 2009-09-10 Methods of using sustained release aminopyridine compositions

Country Status (15)

Country Link
US (3) US20100061935A1 (OSRAM)
EP (1) EP2343976A4 (OSRAM)
JP (1) JP2012502103A (OSRAM)
CN (1) CN101827522A (OSRAM)
AR (1) AR073573A1 (OSRAM)
AU (1) AU2009291781A1 (OSRAM)
BR (1) BRPI0903914A2 (OSRAM)
CA (1) CA2736381A1 (OSRAM)
CL (1) CL2009001841A1 (OSRAM)
PA (1) PA8841801A1 (OSRAM)
PE (1) PE20100264A1 (OSRAM)
RU (1) RU2011113762A (OSRAM)
TW (1) TW201010703A (OSRAM)
UY (1) UY32109A (OSRAM)
WO (1) WO2010030755A1 (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8007826B2 (en) 2003-12-11 2011-08-30 Acorda Therapeutics, Inc. Sustained release aminopyridine composition
US8354437B2 (en) 2004-04-09 2013-01-15 Acorda Therapeutics, Inc. Method of using sustained release aminopyridine compositions
AU2013221604B2 (en) * 2012-02-13 2017-11-23 Acorda Therapeutics, Inc. Methods for treating an impairment in gait and/or balance in patients with multiple sclerosis using an aminopyridine
DE102012103179A1 (de) 2012-04-12 2013-10-17 Sieber Forming Solutions Gmbh Verfahren und Vorrichtung zur spanlosen Herstellung eines Außengewindes auf Werkstücken aus Metall
UY34896A (es) * 2012-07-12 2014-02-28 Teva Pharma Tratamiento de la esclerosis múltiple con una combinación de laquinimod y fampridina
WO2014028387A1 (en) * 2012-08-13 2014-02-20 Acorda Therapeutics, Inc. Methods for improving walking capacity in patients with multiple sclerosis using an aminopyridine
CN104091062A (zh) * 2014-07-03 2014-10-08 刘鸿 基于检验效能的诊断性试验Meta分析的方法
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
PL4252849T3 (pl) 2016-08-31 2025-04-28 Mapi Pharma Ltd. Układ typu depot zawierający octan glatirameru
IL316573A (en) 2017-03-26 2024-12-01 Mapi Pharma Ltd Storage systems containing glatiramer acetate for the treatment of multiple sclerosis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200462B (OSRAM) * 1990-09-27 1993-02-21 Hoechst Roussel Pharma
US6284473B1 (en) * 1995-10-02 2001-09-04 Uab Research Foundation P-cresol sulfate, a component of urinary myelin basic protein-like material, as a correlate of multiple sclerosis status
AU2004226876A1 (en) * 2003-04-03 2004-10-14 Prana Biotechnology Ltd Treatment of neurological conditions
AU2004260702A1 (en) * 2003-08-01 2005-02-10 Ability Biomedical Corporation Combination therapies for Multiple Sclerosis
US8354437B2 (en) * 2004-04-09 2013-01-15 Acorda Therapeutics, Inc. Method of using sustained release aminopyridine compositions
WO2006130726A2 (en) * 2005-06-01 2006-12-07 Teva Pharmaceutical Industries, Ltd. Use of ladostigil for the treatment of multiple sclerosis
ES2746121T3 (es) * 2005-09-23 2020-03-04 Acorda Therapeutics Inc Método, aparato y software para la identificación de respondedores en un entorno clínico

Also Published As

Publication number Publication date
PE20100264A1 (es) 2010-04-28
TW201010703A (en) 2010-03-16
BRPI0903914A2 (pt) 2015-07-21
US20100061935A1 (en) 2010-03-11
AR073573A1 (es) 2010-11-17
AU2009291781A1 (en) 2010-03-18
US20130072527A1 (en) 2013-03-21
CN101827522A (zh) 2010-09-08
WO2010030755A1 (en) 2010-03-18
EP2343976A4 (en) 2011-12-14
EP2343976A1 (en) 2011-07-20
RU2011113762A (ru) 2012-10-20
JP2012502103A (ja) 2012-01-26
US20130330277A1 (en) 2013-12-12
UY32109A (es) 2010-04-30
CL2009001841A1 (es) 2011-02-18
PA8841801A1 (es) 2010-06-28

Similar Documents

Publication Publication Date Title
US20130330277A1 (en) Methods of using sustained release aminopyridine compositions
AU2016219650B2 (en) Compositions and methods for extended therapy with aminopyridines
US20200113883A1 (en) Durable treatment with 4-aminopyridine in patients with demyelination
US20200113882A1 (en) Use of 4-Aminopyridine to Improve Neuro-Cognitive and/or Neuro-Psychiatric Impairment in Patients with Demyelinating and Other Nervous System Conditions
HK1147941A (en) Methods of using sustained release aminopyridine compositions
HK1173911B (en) Use of 4-aminopyridine to improve neuro-cognitive and/or neuro-psychiatric impairment in patients with multiple sclerosis

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140820

FZDE Discontinued

Effective date: 20170215

FZDE Discontinued

Effective date: 20170215